• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
Endogenex

Endogenex

Bringing New Energy to the Treatment of Type 2 Diabetes

  • ReCET
  • Patients
  • Clinical Providers
  • About Us
    • News
    • Contact
  • Clinical Studies
Full 1

Bringing new energy to the treatment of Type 2 Diabetes

Full 1

Learn about Type 2 Diabetes and options to take control of your health.

Full 1

Resetting treatment options for people living with Type 2 Diabetes.

previous arrow
next arrow

Committed to improving the treatment of Type 2 Diabetes

Endogenex is creating a novel approach to address the challenges that Type 2 Diabetes brings to patients, providers and healthcare systems around the world. 

Through a partnership with Mayo Clinic, Endogenex, has developed the ReCETTM Procedure, based on the principle of metabolic change through Intestinal Cellular Regeneration (ICR). The ReCET Procedure is investigational and under evaluation in clinical studies. The procedure is designed to promote better blood glucose control and potentially slow the progression of Type 2 Diabetes. 

Global impact of Type 2 Diabetes

400+

million

people worldwide are living with Type 2 Diabetes1

50%

of people

living with diabetes have a poorly controlled HbA1c2

$327

billion

in total cost of diagnosed diabetes in the United States3

Introducing ReCET™

The ReCET ICR Procedure applies the unique capabilities of pulsed electric fields with a novel endoscopic approach that together are intended to restore the natural signaling process of the duodenum that helps the body better control blood glucose levels.

Through this outpatient procedure, Endogenex aims to provide patients with better blood glucose control, give providers a non-pharmacologic treatment option for their patients and reduce the burden that Type 2 Diabetes places on global healthcare systems.

Learn about ReCET

In the news

Endogenex

Endogenex™ Appoints Medical Device Executive, Stacey Pugh, Chief Executive Officer

7News Australia report: Clinical study evaluating technology to treat Type 2 Diabetes being expanded

Clinical study participant with Type 2 Diabetes shares his story

“There needs to be a paradigm shift in the way we treat diabetes, from focusing on the downstream effects…to trying to reset the metabolic clock and push back the natural disease process.”
— Barham K. Abu Dayyeh, M.D., M.P.H.
Co-inventor, ReCET Technology

* Caution: Exclusively a clinical investigational device. Limited by federal (or United States or similar) law to investigational use. Not for sale in any geography.

Endogenex, Inc.
151 Cheshire Ln N #400
Plymouth, MN 55441
+1 763-251-6820
info@endogenex.com

  • Facebook
  • Twitter
  • LinkedIn
  • Vimeo

References

Terms of Use

Privacy Policy

Cookie Policy

Join our mailing list


EndogenexTM and ReCETTM are registered trademarks of Endogenex, Inc. in the United States and other countries.

Copyright © 2023 Endogenex, Inc. All rights reserved.